AptarGroup Says Its Proprietary Nasal Delivery System Is Utilized In LTR Pharma's Phase II Clinical Study Of SPONTAN, Investigational Intranasal Spray Under Development For Treatment Of Erectile Dysfunction

AptarGroup, Inc. (NYSE: ATR) announced that its proprietary nasal delivery system is being used in LTR Pharma Limited's (ASX: LTP) Phase II clinical study of SPONTAN®, an investigational intranasal spray for treating erectile dysfunction. This development highlights Aptar's commitment to advancing intranasal drug delivery technologies and innovative therapies.